LONDON-- GlaxoSmithKline PLC (GSK.LN) Monday said results from a new study shows that its treatment Nucala significantly improves quality of life and lung function in severe asthma patients.

Shares at 1453 GMT, down 2 pence, or 0.09%, at 1,686 pence valuing the company at GBP82.9 billion.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

March 06, 2017 10:09 ET (15:09 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more GSK Charts.